Increased Lymphocyte Proportions as a Candidate Biomarker for Immune‐Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy
Cancer Medicine · 2026
DOI: 10.1002/cam4.72361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Nanami Ito und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Neoplasms, Lymphocytes. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science London.
Themen: Patientensicherheit, Onkologische Pflege
Abstract (Originalsprache)
Background
Combination therapy comprising immune checkpoint inhibitors (ICIs) and chemotherapy is standard treatment for many cancer types. However, the management of adverse events (AEs) induced by combination therapy is more complicated than that of AEs induced by ICI monotherapy. Although immune‐related AEs (irAEs) induced by ICIs and AEs induced by chemotherapy require distinct therapeutic approaches, distinguishing between them can be challenging. Therefore, in this exploratory study, we aimed to investigate whether lymphocyte proportion could serve as a candidate biomarker associated with the occurrence of irAEs in patients receiving ICI plus chemotherapy combination therapy. Patients and Methods We categorized 122 patients into the irAE group (those who experienced irAEs), chemo‐AE group (those with chemotherapy‐induced AEs), and non‐AE group (those without AEs) and analyzed their lymphocyte proportions before one course (baseline sample) and two courses (two‐course sample) of treatment.
Results
Lymphocyte proportions of the baseline samples did not differ between the non‐AE, chemo‐AE, and irAE groups. The lymphocyte proportion of the two‐course sample of the irAE group was significantly higher than that of the non‐AE group (25.8% vs. 21.9%; p < 0.05). The lymphocyte proportion of the two‐course sample of the irAE group was significantly higher than that of the chemo‐AE group (25.8% vs. 19.6%; p < 0.05). The multivariate logistic regression analysis showed that a lymphocyte proportion ≥ 23.9% in the two‐course sample significantly increased the risk of irAEs (odds ratio = 3.04; p < 0.05).
Conclusions
An increased lymphocyte proportion before the two courses of treatment was associated with the occurrence of irAEs and may serve as a candidate biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Respiratory Medicine, Allergy, and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Thoracic and Pediatric Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
- Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
ORCID-Profile: Yoshihiko Tasaki, Yosuke Sugiyama, Ryo Ogawa, Takaya Shimura, Daisuke Kawakita, Yoshihisa Mimura, Kunihiro Odagiri, Yuji Hotta, Shinichi Iwasaki, Akio Niimi, Yoko Furukawa-Hibi
Förderung
- Japan Society for the Promotion of Science London
Zitieren
APA
Ito, N., Tasaki, Y., Sugiyama, Y., Uemura, T., Yokota, K., Ogawa, R., Shimura, T., Kawakita, D., Wanifuchi-Endo, Y., Mimura, Y., Iida, M., Odagiri, K., Kimura, Y., Tomita, M., Hotta, Y., Toyama, T., Iwasaki, S., Kataoka, H., Takiguchi, S., …, & Furukawa-Hibi, Y. (2026). Increased Lymphocyte Proportions as a Candidate Biomarker for Immune‐Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy. Cancer Medicine. https://doi.org/10.1002/cam4.72361
Vancouver
Ito N, Tasaki Y, Sugiyama Y, Uemura T, Yokota K, Ogawa R, et al. Increased Lymphocyte Proportions as a Candidate Biomarker for Immune‐Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy. Cancer Medicine. 2026. doi:10.1002/cam4.72361
BibTeX
@article{Ito2026,
author = {Ito, Nanami and Tasaki, Yoshihiko and Sugiyama, Yosuke and Uemura, Takehiro and Yokota, Keisuke and Ogawa, Ryo and Shimura, Takaya and Kawakita, Daisuke and Wanifuchi-Endo, Yumi and Mimura, Yoshihisa and Iida, Moeko and Odagiri, Kunihiro and Kimura, Yuka and Tomita, Misato and Hotta, Yuji and Toyama, Tatsuya and Iwasaki, Shinichi and Kataoka, Hiromi and Takiguchi, Shuji and Okuda, Katsuhiro and Niimi, Akio and Furukawa-Hibi, Yoko},
title = {Increased Lymphocyte Proportions as a Candidate Biomarker for Immune‐Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72361}
}
EUVIMED